Polaryx Therapeutics, Inc.
PLYX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002075320
No open-market purchases or sales by Polaryx Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $5.83M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Polaryx Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 14 | 13 | −1 |
| Shares | 2.27M | 2.19M | −74.0K (−3.3%) |
| Value | $17.1M | $5.83M | −$11.3M (−66.0%) |
New holders (4)
Institutions that held Polaryx Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 82,094 | $218.0K | 0.00% |
| Jane Street Group, LLC | 31,441 | $83.6K | 0.00% |
| Allworth Financial LP | 7,727 | $20.6K | 0.00% |
| Fortitude Family Office, LLC | 189 | $503 | 0.00% |
Sold out (5)
Institutions that held Polaryx Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Millennium Management LLC | 127,525 | $964.1K |
| Bank of America Corp | 25,881 | $195.7K |
| Goldman Sachs Group Inc | 13,483 | $101.9K |
| Squarepoint Ops LLC | 12,406 | $93.8K |
| Morgan Stanley | 5,543 | $41.9K |